Parkinson's disease (PD) is defined by the loss of dopaminergic neurons in the substantia nigra and the formation of Lewy body inclusions containing aggregated a-synuclein. Efforts to explain dopamine neuron vulnerability are hindered by the lack of dopaminergic cell death in a-synuclein transgenic mice. To address this, we manipulated both dopamine levels and a-synuclein expression. Nigrally targeted expression of mutant tyrosine hydroxylase with enhanced catalytic activity increased dopamine levels without damaging neurons in non-transgenic mice. In contrast, raising dopamine levels in mice expressing human A53T mutant a-synuclein induced progressive nigrostriatal degeneration and reduced locomotion. Dopamine elevation in A53T mice increased levels of potentially toxic a-synuclein oligomers, resulting in conformationally and functionally modified species. Moreover, in genetically tractable Caenorhabditis elegans models, expression of a-synuclein mutated at the site of interaction with dopamine prevented dopamine-induced toxicity. These data suggest that a unique mechanism links two cardinal features of PD: dopaminergic cell death and a-synuclein aggregation.
a r t I C l e S PD is a debilitating neurodegenerative disorder that is principally defined by the motor symptoms of resting tremor, rigidity and bradykinesia. These symptoms occur primarily because of the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SN), which depletes dopamine at nigrostriatal synapses 1 . A longstanding hypothesis to explain the vulnerability of this cell population states that dopamine induces neuronal injury via oxidative stress. The enzyme-or metal-catalyzed oxidation of dopamine generates electron-deficient quinones and reactive oxygen species that can induce cellular dysfunction 2, 3 . The SN in PD patients is reported to harbor oxidatively modified proteins, lipids and nucleic acids [4] [5] [6] . Efforts to study the effects of dysregulated dopamine in animal models have included ectopic dopamine administration and increased cytosolic dopamine by suppression of vesicular monoamine transporter (VMAT2) expression [7] [8] [9] .
More recently, α-synuclein has emerged as a critical player in PD pathogenesis. Disturbances in α-synuclein protein folding or expression level, that is, through mutations or extra copies of the gene that encodes it, SNCA, are known causes of PD [10] [11] [12] [13] [14] [15] [16] [17] . In both familial and sporadic cases, aggregated α-synuclein is present in Lewy bodies and Lewy neurites, which are the hallmark pathological lesions of the disease 18, 19 . α-synuclein is a small, highly conserved protein (140 residues) that is abundantly expressed in the nervous system primarily at presynaptic terminals 20 . The precise physiological functions of α-synuclein remain unclear, although it is thought to have diverse roles in synaptic maintenance and plasticity, neurotransmitter release and homeostasis, and the regulation of synaptic vesicle pools [21] [22] [23] . In disease, α-synuclein assembles into β-sheet-rich amyloid-like fibrils, generating several intermediate oligomeric species of unknown toxicity 24 .
Notably, α-synuclein oligomers are kinetically stabilized by oxidized dopamine and other catecholamines in vitro 24, 25 , providing a possible link between dopamine-and α-synuclein-mediated toxicities. Extensive evidence from cultured cells and cell-free systems indicates that dopamine potently and substoichiometrically inhibits the fibrillization of α-synuclein, resulting in the kinetic arrest of soluble oligomer species. Dopamine oxidation is required for oligomer stabilization, suggesting that α-synuclein interacts with dopamine-quinone and/or other oxidation products. The interaction is non-covalent, reversible and dependent on residues E 83 and the Y 125 EMPS 129 motif in the C terminus of α-synuclein [24] [25] [26] [27] [28] . The toxicity of these oligomers is largely unexplored, although in vitro dopamine-incubated α-synuclein is reported to interfere with and resist degradation by chaperone-mediated autophagy 29 and to inhibit SNARE complex formation and neurotransmitter release 30 . It is unknown whether dopamine is able to modify α-synuclein oligomerization in vivo and whether the a r t I C l e S resultant species are capable of driving neurodegeneration. These are the critical questions we sought to answer.
RESULTS

Expression of TH-RREE elevates dopamine levels and causes hyperactivity in NonTg mice
To increase dopamine levels in vivo, we used a lentiviral vector containing the TH gene encoding human tyrosine hydroxylase (TH). TH is the rate-limiting enzyme in dopamine biosynthesis converting tyrosine to L-DOPA, which is then metabolized by aromatic amino acid decarboxylase to generate dopamine. A mutated TH enzyme that has R 37 R 38 replaced with E 37 E 38 (TH-RREE) is insensitive to feedback inhibition by dopamine and can be used to achieve increased catalytic activity of TH 26, 27, 31 . We first tested the function of the vector on human neuroblastoma SH-SY5Y cells. This cell line has undetectable levels of endogenous TH, despite the expression of other enzymes required for synthesis and processing of dopamine. We transduced the cells after 5 d of differentiation with 20 µM retinoic acid and confirmed TH expression by western blot and immunocytochemistry compared with empty vector (CtrlVect)-transduced controls (Supplementary Fig. 1a-c) . The TH-RREE transduced cells had measurable intracellular levels of L-DOPA, dopamine and DOPAC in the range of 25-200 fmol µg −1 , whereas catecholamines were not detected in CtrlVect-transduced cells (Supplementary Fig. 1d ), indicating that TH-RREE vector enhances catecholamine production.
We performed bilateral injections of TH-RREE vector into the SN of aged (10 month old) nontransgenic (NonTg) mice. This age was selected because the mice expressing A53T mutant human α-synuclein are asymptomatic and do not exhibit the characteristic motor phenotype derived from spinal cord degeneration 32 . The typical age of onset of this phenotype in our colony was approximately 18 months. At 5 months post-injection (mpi), TH expression was increased in both SN and striatum in NonTg TH-RREE mice compared with agematched NonTg CtrlVect mice ( Fig. 1a,b) . TH-RREE significantly elevated striatal concentrations of L-DOPA and dopamine by 36% (P = 0.0235) and 52% (P = 0.0137), respectively, whereas DOPAC was not affected. Notably, 5-HT levels did not change, indicating that the effect was specific for the catecholamine neurotransmitter system (Fig. 1c) . Consistent with elevated striatal dopamine, NonTg TH-RREE mice exhibited hyperactivity in open field-testing compared with NonTg CtrlVect mice ( Fig. 1d) . There was no difference in rotarod performance between the NonTg injection groups (Fig. 1e) .
These data indicate that the TH-RREE vector substantially enhanced dopamine levels fully 5 months following injection.
Dopamine-induced neurodegeneration and motor deficit is dependent on a-synuclein expression
Bilateral injection of the TH-RREE vector into the SN of 10-monthold A53T mutant α-synuclein mice also resulted in TH overexpression ( Supplementary Fig. 2 ). However, in contrast with NonTg mice, A53T TH-RREE mice exhibited striatal degeneration and neuronal loss in the SN at 5 mpi. To circumvent detection of vector-encoded TH, we used another marker of dopaminergic neurons, VMAT2, to evaluate neuronal loss. A53T TH-RREE mice had fewer VMAT2-positive a r t I C l e S cells in the SN than any of the other injection groups ( Fig. 2a) . We quantified the loss of neurons using unbiased stereological counting of Nissl cells, which revealed a significant 25% reduction in A53T TH-RREE mice compared with controls ( Fig. 2b) . The number of neurons quantified in age-matched A53T CtrlVect, as well as NonTg CtrlVect and NonTg TH-RREE mice, was typical for the mouse SN 33 , indicating that neurodegeneration had not occurred in these mice (Fig. 2b) .
The degeneration of cell bodies was accompanied by a significant 62% decrease in VMAT2 staining in the striatum of A53T TH-RREE mice, indicating that there was a severe loss of dopaminergic nerve terminals ( Fig. 2c,d) . Denervation of the striatum was further corroborated by quantification of dopamine transporter (DAT) levels, which revealed a significant 55% decline (P = 0.0211) in A53T TH-RREE mice compared with A53T CtrlVect. In contrast, the levels of DAT were twofold higher in NonTg TH-RREE than in NonTg CtrlVect mice ( Fig. 2e,f) . DAT upregulation may serve to compensate for increased dopamine levels, and may not be apparent in A53T TH-RREE mice as a result of the substantial loss of dopaminergic terminals. The injury in A53T mice appears to be primarily presynaptic in that levels of D1 receptors remained unchanged ( Supplementary Fig. 3a,b) . Levels of dopamine-and cAMP-regulated phosphoprotein-32 (DARPP-32), which serves as an important signaling molecule in spiny projection neurons, were also unaffected ( Supplementary Fig. 3a,c) .
To further investigate the progressive degenerative phenotype in A53T TH-RREE mice, we quantified the total number of SN neurons at the earlier time point of 2.5 mpi. No difference was observed between A53T CtrlVect and TH-RREE mice, indicating that cell loss had not yet occurred ( Fig. 3a) . Despite the maintenance of neuronal cell bodies, striatal VMAT2 levels were decreased by 25% ( Fig. 3b) , revealing a milder loss of nerve terminals than at the later time point of 5 mpi ( Fig. 2c-d) . Consistent with progressive degeneration of synapses, we noted a time-dependent decline of striatal dopamine content in A53T TH-RREE mice. At 2.5 mpi, dopamine was increased significantly by 71% compared with age-matched A53T CtrlVect mice as a result of mutant TH expression ( Fig. 3c) . However, A53T TH-RREE mice subsequently exhibited a 37% drop in dopamine concentration between 2.5 and 5 mpi, whereas A53T CtrlVect mice showed no change during the same period ( Fig. 3c) . (e,f) Striatal DAT levels normalized to the actin loading control were increased in NonTg TH-RREE mice relative to NonTg CtrlVect, whereas DAT levels were decreased in A53T TH-RREE mice as compared to A53T CtrlVect. Blots are cropped; for full-length blots see Supplementary Figure 11 (n = 3 mice per group except n = 4 mice for NonTg CtrlVect, P A53T TH-RREE versus A53T CtrlVect = 0.0211, P A53T CtrlVect versus NonTg CtrlVect = 0.0097, P NonTg TH-RREE versus NonTg CtrlVect = 0.0466, F (3, 9) = 8.411; one-way ANOVA with Tukey's correction for multiple comparisons). Box plots show median, 25th and 75th percentiles, and minimum and maximum values. *P < 0.05, **P < 0.01. a r t I C l e S The reduction in dopamine levels cannot be explained by increased conversion to DOPAC, as levels of this metabolite remained unchanged from 2.5 to 5 mpi ( Fig. 3d) . We also did not detect an increase in dopamine-protein adducts by near infrared fluorescence ( Supplementary Fig. 4) . Rather, the loss of dopamine is likely a result of the ongoing nigrostriatal degeneration documented in these mice. Concomitant with the decrease in dopamine levels, A53T TH-RREE mice exhibited a significant impairment in ambulatory activity that was not apparent at 2.5 mpi, but emerged by 5 mpi (Fig. 3e) . Performance on the rotarod remained intact, suggesting that balance and coordination were not disrupted ( Fig. 3f) . Collectively, the results indicate that enhanced production of dopamine promotes the progressive degeneration of dopaminergic neurons and a specific motor deficit in mice that express A53T α-synuclein, but not in NonTg mice.
Dopamine modifies a-synuclein oligomer conformations in A53T mice
These data indicate that increased steady state levels of dopamine result in neurotoxicity in an α-synuclein-dependent manner. To investigate possible mechanisms, we examined the influence of dopamine on α-synuclein aggregation and, in particular, the kinetic stabilization of potentially toxic α-synuclein oligomers. The presence of Lewy-body-like inclusions in circumscribed regions, including the brainstem of aged A53T mice, has been well-documented 32 . α-synuclein-positive inclusions were indeed detected in the brainstem of A53T TH-RREE mice at 5 mpi (age 15 months), similar to age-matched A53T CtrlVect mice ( Supplementary Fig. 5a ). In contrast, the SN is known to remain devoid of inclusions during the lifespan of A53T mice 32 . Expression of TH-RREE vector did not induce α-synuclein inclusion formation or alter levels or conformations of detergent-insoluble α-synuclein in the SN at 5 mpi ( Supplementary Fig. 5 ).
Examination of detergent-soluble α-synuclein extracted from SN of A53T mice at 5 mpi revealed substantial alterations in the quantities and conformations of α-synuclein species as a result of dopamine elevation. A53T TH-RREE mice had a significant 22% reduction in monomeric human α-synuclein compared with A53T CtrlVect mice ( Fig. 4a,b) . Following fractionation of the soluble SN extract by native size exclusion chromatography (SEC), we detected the presence of a r t I C l e S various oligomeric α-synuclein species of different molecular weights ( Fig. 4c) . Quantification of total oligomeric species revealed a significant increase in A53T TH-RREE mice, greater than twofold above that in A53T CtrlVect mice ( Fig. 4d) . To characterize the oligomers, we used multiple α-synuclein antibodies and a combination of SDS-PAGE, immunoelectron microscopy and biochemical assays. In A53T CtrlVect mice, oligomers had Stokes radii of up to 65 Å and ranged in molecular weight from 36 to 80 kDa ( Fig. 4c and Supplementary  Fig. 6a,b) , consistent with previous observations 34 . However, in addition to these low-angstrom species, larger species of up to 122 Å were detected in A53T TH-RREE mice. On 12% SDS-PAGE, these species migrated as dimers, trimers and high-molecular-weight polymers stable to SDS and heat, consistent with the presence of oxidized and crosslinked species 35 . The appearance of unique, high-angstrom species in A53T TH-RREE mice was observed with multiple α-synuclein antibodies that recognize N-or C-terminal epitopes ( Fig. 4c and Supplementary Fig. 6a,b) . Moreover, analysis of quinone-associated protein by near-infrared fluorescence revealed that only the high-angstrom oligomeric fractions from A53T TH-RREE mice were positive, supporting a direct interaction of dopamine and α-synuclein oligomers in these mice (Supplementary Fig. 6c ).
Further structural analysis of oligomers isolated from high-(72-122) or low-angstrom (41-65) SEC fractions was undertaken by immunoelectron microscopy. Oligomers typically appeared as clusters with >2 gold particles in both high-and low-angstrom fractions from A53T TH-RREE mice, as well as low-angstrom fractions from A53T CtrlVect mice. The species were labeled with α-synuclein antibodies directed at either the N-or C terminus, indicating that both ends were exposed ( Fig. 4e) . Clusters of >2 gold particles were not observed in high-angstrom fractions from A53T CtrlVect mice or fractions from A53T TH-RREE mice that were immunodepleted of α-synuclein before imaging. Similar to mouse-derived oligomers, oligomers generated from incubating purified recombinant human wild-type α-synuclein with dopamine in vitro migrated as 36-to >98-kDa bands on SDS-PAGE and were recognized by both N-and C-terminally directed α-synuclein antibodies in western blots and by immunoelectron microscopy (Supplementary Fig. 7c,d) . Electron microscopy imaging of the recombinant oligomers revealed clusters of >2 gold particles as observed in oligomer fractions from mouse SN (Supplementary Fig. 7d) .
Given that there is growing evidence for prion-like spreading of α-synuclein pathology in disease 36 , we investigated whether dopamine a r t I C l e S promotes in vivo formation of oligomeric species with the capacity for templated propagation. α-synuclein oligomers extracted from A53T TH-RREE or A53T CtrlVect mice (pooled 41-122-Å SEC fractions) were monitored in a seeding assay with fresh recombinant α-synuclein in vitro. In the case of A53T CtrlVect mice, oligomers efficiently seeded aggregation relative to the no-seed condition, as measured by Thioflavin T (Fig. 4f) . Notably, this effect was abolished by prior immunodepletion of α-synuclein from the SEC fractions. In contrast, the same fractions from TH-RREE mice were unable to act as seeds ( Fig. 4f ), suggesting that seeding-competent species were not retained following the interaction of α-synuclein with dopamine in vivo. We also did not detect dopamine-modified oligomers in the motor cortex of A53T TH-RREE mice (Supplementary Fig. 8 ), suggesting that these species do not spread trans-synaptically. Collectively, these data indicate that dopamine promotes the generation of conformationally and functionally modified α-synuclein oligomeric species in the mouse brain.
To further establish the link between dopamine-induced oligomers and toxicity, we exposed primary neuronal cultures to recombinant α-synuclein oligomers generated in the presence of dopamine in vitro. Exogenous α-synuclein from oligomer preparations had become internalized in neurons and localized to neurites by 2 weeks posttreatment ( Supplementary Fig. 9a ). At this time point, we evaluated cells for viability using Calcein AM and propidium iodide (PI) dyes. Exposure of neurons to 1 µM dopamine-incubated α-synuclein induced a significant 44% reduction in Calcein-positive, PI-negative cells relative to phosphate-buffered saline (PBS)-treated controls ( Supplementary Fig. 9b,c) . Treatment with equivalent doses of monomeric α-synuclein, or dopamine that had been incubated under aggregation conditions without α-synuclein, did not reduce cell viability (Supplementary Fig. 9b,c) . The observed neurotoxicity can therefore be attributed specifically to α-synuclein oligomers, consistent with our findings in vivo linking dopamine-modified species with severe nigrostriatal degeneration.
Disrupting the interaction of dopamine and a-synuclein mitigates neurotoxicity in C. elegans To gain further mechanistic insight into the synergistic toxicity of dopamine and α-synuclein, we took advantage of the genetic tractability of the nematode model system Caenorhabditis elegans. Previous studies have shown that expressing human wild-type or PD-linked mutants of α-synuclein in dopaminergic neurons of C. elegans causes progressive age-dependent neurodegeneration [37] [38] [39] [40] . Overexpression of the TH homolog CAT-2 also induces dopamine neuron loss in worms 38 . To test the combined effect of these factors on neuronal health, we first generated transgenic worms expressing human A53T α-synuclein under the control of the worm dopamine transporter (dat-1) promoter. C. elegans hermaphrodites have precisely eight dopamine neurons, which we visualized by coexpressing P dat-1 ::GFP. Consistent with previous C. elegans models of A53T α-synuclein toxicity, we documented that 62% and 50% of A53T worms maintained normal dopamine neurons on days 5 and 6 post-hatching, respectively ( Fig. 5) . Notably, CAT-2 overexpression in A53T worms significantly exacerbated the degeneration of dopamine neurons, with only 33% and 26% of worms exhibiting normal neurons at days 5 and 6, respectively ( Fig. 5) . These data are consistent with our observations in the A53T TH-RREE mouse model and suggest that neuronal susceptibility to dopamine/α-synuclein toxicity is conserved.
We next investigated whether mutating α-synuclein at the site of interaction with dopamine would rescue neurons from degeneration. Mutation of the Y 125 EMPS 129 motif in the C terminus of α-synuclein to F 125 AAFA 129 abolishes the interaction with dopamine and inhibits dopamine-mediated stabilization of oligomers 25, 27 . Transgenic worms expressing A53T α-synuclein with the F 125 AAFA 129 mutation [A53T(125-9m)] at similar levels as A53T α-synuclein showed no difference in dopamine neuron degeneration compared with A53T worms ( Fig. 5 and Supplementary Fig. 10 ). However, A53T(125-9m) worms displayed complete resistance to CAT-2-induced neurodegeneration, with the percentage of worms exhibiting normal dopamine neurons restored to 66% and 49% on days 5 and 6, respectively (Fig. 5) . These findings suggest that the specific interaction of dopamine with the C terminus of α-synuclein is a critical contributor to the degeneration of dopamine neurons in vivo. The demonstration of this phenomenon in two in vivo platforms (worms and mice) strongly supports a role for dopamine-induced oligomers in the mechanism of neurotoxicity. 
DISCUSSION
We used a new approach to enhance nigrostriatal dopamine levels in A53T mutant human α-synuclein transgenic mice. In this well-characterized mouse model, the SN does not develop α-synuclein inclusions and does not undergo neuronal cell loss 32 . However, elevation of dopamine levels in the A53T mice induced substantial nigrostriatal degeneration and a previously undescribed locomotor impairment. Neurodegeneration was not observed in NonTg mice receiving the same treatment, indicating that dopamine-induced toxicity is dependent on α-synuclein. To the best of our knowledge, this is also the first demonstration that dopamine promotes α-synuclein oligomerization in vivo and that disrupting the ability of dopamine to stabilize/modify oligomers rescues neurons from dopamine toxicity. Taken together, these findings suggest that dopamine-induced α-synuclein oligomers may be a promising new target for PD treatment.
Dopamine has long been considered a contributor to the death of dopaminergic neurons in disease 3 . At cytosolic pH, dopamine autooxidizes to form reactive quinone species, hydrogen peroxide and other electrophiles 2 . The notion that dopamine may be neurotoxic has resulted in the widespread practice of 'DOPA sparing' , which delays administration of the highly effective symptomatic therapy L-DOPA until more advanced stages of the disease. Although there is presently no conclusive evidence indicating that L-DOPA accelerates PD progression, clinical trials have provided mixed results and the issue of L-DOPA toxicity remains, unfortunately, unresolved 41, 42 . Despite the importance of investigating catecholamine toxicity, there are few studies in animal models. Single high-dose injections of dopamine into the striatum of rats have been shown to be acutely toxic in the short timeframe of 1 week 7 . Other reports have shown that redistribution of endogenous dopamine to the cytosol is associated with toxicity in VMAT2 mutant mice 8, 9 . However, the long-term effects of increasing nigrostriatal dopamine levels remain unknown.
Our experiments represent the first investigation of dopamine toxicity by chronic enhancement of dopamine synthesis in mice. By expressing mutant TH that is insensitive to feedback inhibition by dopamine 26, 27, 31 , we found that striatal dopamine in NonTg mice was increased by over 50%. To our surprise, this substantial perturbation of dopamine homeostasis was insufficient to induce degeneration. NonTg TH-RREE mice maintained a normal number of SN neurons, intact synaptic contacts with the striatum and robust motor coordination/balance. The excess dopamine was likely released into the synapse, leading to the observed hyperactivity, which is consistent with other studies 43 . It is possible the excess dopamine was well tolerated as a result of compensatory upregulation of metabolic enzymes and transporters; indeed, there was a substantial increase in DAT levels in these mice.
α-synuclein has been independently linked to PD through dominantly inherited mutations and multiplications of the SNCA gene [10] [11] [12] [13] [14] [15] [16] [17] , and by the presence of aggregated α-synuclein in Lewy bodies and Lewy neurite inclusions 18, 19 . However, efforts to model PD by α-synuclein overexpression in transgenic mice have often resulted in a lack of inclusion pathology and neurodegenerative changes in the SN. Dopaminergic neurons are entirely spared in the A53T transgenic mouse model that we used 32 , and we documented a normal complement of neuronal cell bodies and terminals and a lack of intraneuronal α-synuclein inclusions in the SN in A53T CtrlVect mice. This may be related to several factors, including the fact that mouse α-synuclein naturally has a threonine at position 53. In vitro, mouse α-synuclein fibrillizes more rapidly than human wild-type or A53T α-synuclein, and yet aged mice do not spontaneously develop α-synuclein inclusions or a PD-like disorder 44 . It is likely that mice have evolved protective mechanisms against α-synuclein aggregation, such as an enhanced ability to maintain α-synuclein in a physiological lipidor protein-bound state, and that these mechanisms may counteract efforts to initiate disease by transgenic α-synuclein expression.
Our study offers another possible explanation for the challenges of producing SN neurodegeneration in α-synuclein transgenic mice: lack of dopamine dysregulation. In stark contrast with NonTg mice, elevation of dopamine levels in A53T mice resulted in progressive nigrostriatal degeneration with locomotor impairment, markedly improving this mouse as a model of PD. Similarly, coexpression of CAT-2 and A53T α-synuclein in C. elegans induced more severe dopamine neuron degeneration than A53T α-synuclein expression alone. These findings are consistent with a limited number of studies reporting toxicity associated with the convergence of dopamine and α-synuclein. In the case of VMAT2-deficient mice, loss of SN neurons was only observed in animals on a normal α-synuclein background, whereas identical reduction of VMAT2 in animals with Snca gene locus deletion did not result in cell loss 8, 9, 45 . In C. elegans expressing wild-type human α-synuclein, increasing cytosolic dopamine by mutation of the worm homolog of VMAT2 accelerated neurodegeneration. Conversely, protection from neuronal loss has been reported for worms expressing wild-type human α-synuclein and a nonfunctional mutant of CAT-2 that prevents dopamine synthesis 40 . In addition, in rodent midbrain cultures, elevating cytosolic dopamine concentration reduces dopaminergic cell survival, and this effect is dependent on α-synuclein 46 .
The synergistic toxicity of dopamine and α-synuclein may be mediated by α-synuclein oligomers, which are thought to be neurotoxic species. Lentiviral vector delivery of artificial α-synuclein variants with enhanced oligomerization into the rat SN resulted in the selective loss of dopaminergic cells 47 . Similarly, artificial mutants with impaired β-sheet structure and increased propensity to form oligomers induced degeneration of dopaminergic nerve terminals in worms and overt dopaminergic cell loss in flies 39 . In addition, oligomer-containing extracts from A53T transgenic mice were toxic when applied to primary mouse cortical cultures 34 . Although it is known that oxidized dopamine kinetically stabilizes soluble α-synuclein oligomers in cell-free systems 24, 25 and in SH-SY5Y cultures 26, 27 , the toxicity of these species is largely unexplored. Evidence from studies conducted in vitro suggests that dopamine-induced oligomers can block their own degradation and that of other substrates by chaperone-mediated autophagy 29 , and can reduce neurotransmitter release by inhibition of SNARE complex formation 30 . In human fetal dopaminergic cultures, reduced viability was linked to endogenous dopamine and the accumulation of soluble α-synuclein protein complexes 48 .
Notably, the effects of dopamine on α-synuclein oligomerization in vivo have not been investigated. Thus, we sought to determine whether A53T TH-RREE mice had alterations in oligomer biochemical and/or functional properties. Soluble α-synuclein oligomers were extracted from the SN and enriched by SEC under non-denaturing conditions to preserve native conformations. Increasing dopamine resulted in greater total levels of α-synuclein oligomers detected by western blot. The oligomers included species with Stokes radii of up to 65 Å that were also detected in A53T CtrlVect mice, consistent with previous characterization of oligomers in aged A53T mice 34 . Larger oligomers of up to 122 Å were uniquely observed in A53T TH-RREE mice, suggesting that dopamine is capable of modifying oligomer conformations. These species may reflect dopamine-induced remodeling of existing oligomers and/or formation of oligomers from α-synuclein monomers de novo. In addition, oligomers with larger Stokes radii may contain a greater number of monomer units than lower angstrom species, and/or occupy less compacted arrangements. a r t I C l e S Multiple biochemical and imaging approaches were employed to characterize the oligomers extracted from the SN. In addition to well-established methods such as western blotting and SEC, immunoelectron microscopy was performed on SEC fractions to visualize mouse-derived α-synuclein oligomers. Currently, there is no accepted method of specifically imaging α-synuclein oligomers in brain tissue in situ. However, with our approach, we were able to identify and image oligomers of known Stokes radii. Oligomer species from both A53T TH-RREE and A53T CtrlVect mice were labeled with antibodies directed at the N-or C terminus of α-synuclein, suggesting that epitopes at both ends of the protein were exposed. These epitopes were also exposed in soluble α-synuclein oligomers generated with dopamine in vitro, consistent with previous imaging by immunoelectron microscopy 25 . Furthermore, LB509 and Syn505 antibodies are known to react robustly with α-synuclein in pathological inclusions in human disease brain 19, 32 . The reactivity of both mouse-derived and recombinant oligomers with these antibodies suggests that they may share disease-associated conformations.
Unlike the α-synuclein species extracted from A53T CtrlVect mice, oligomers from A53T TH-RREE mice were unable to act as seeds for α-synuclein fibrillization in vitro. In addition, we did not detect dopamine-modified oligomers in cortical tissue from A53T TH-RREE mice. These data argue against both intracellular and intercellular prion-like propagation of these species. Although α-synuclein aggregates that exhibit prion-like behavior have been shown in many contexts to be cytotoxic 34, 36 , seeding ability is neither necessary nor sufficient for toxicity. In a comparison of different oligomer species generated in vitro, α-synuclein oligomers that were toxic to SH-SY5Y cultures were also incapable of seeding intracellular aggregation of α-synuclein. Conversely, seeding-competent oligomers were found to be non-toxic when applied to SH-SY5Y cells 49 . Although the spread of α-synuclein pathology in PD may primarily be driven by self-replicating seeding and cell-to-cell transmission, toxicity may depend on the interaction of aggregates with cell-type-specific factors. In this regard, dopamine may act as an enhancer of oligomer toxicity. Moreover, dopamine-modified species may resist sequestration into non-toxic fibrils or inclusions, and may therefore be available to participate in pathological interactions that ultimately lead to neuron death.
Although the mouse data clearly demonstrate an association between the neurodegenerative/locomotor disease phenotype and the presence of modified and more abundant α-synuclein oligomers, the functional evidence from our transgenic C. elegans models further establishes this link. It is well-documented that the Y 125 EMPS 129 motif in α-synuclein is required for the stabilization of α-synuclein oligomers by dopamine in vitro. Mutation or deletion of this motif restores the ability of α-synuclein to fibrillize in the presence of dopamine 25 , and the increase in oligomeric species in SH-SY5Y cells with elevated dopamine is prevented by expression of α-synuclein that lacks this region 27 . Worms expressing A53T α-synuclein specifically mutated in the Y 125 EMPS 129 domain were entirely resistant to the neurotoxic effects of increasing dopamine levels. Thus, preventing the interaction of dopamine and α-synuclein and thereby inhibiting its effects on α-synuclein oligomers is neuroprotective. Although we were not able to biochemically characterize α-synuclein oligomer species in these worms as a result of expression in only eight cells in the entire animal, our findings nevertheless support a key role of dopamine in neurodegeneration, specifically through its influence on α-synuclein.
Collectively, our findings underscore the potential critical importance of the interaction of dopamine and α-synuclein in driving disease. In PD, dopaminergic terminals are thought to degenerate before cell bodies 50 , suggesting that the disease may arise at the synapse.
Increasing dopamine levels in A53T mice recapitulated the substantial loss of terminals that precedes overt nigral cell death, offering a new model of disease progression in PD. These mice also underwent an eventual decline in dopamine levels and developed an associated motor deficit, mimicking the depletion of striatal dopamine and the resulting hypokinesia that occurs in PD. Our findings also demonstrate that dopamine modifies α-synuclein aggregation in vivo, resulting in oligomer conformations that are biochemically and structurally similar to neurotoxic oligomers induced by dopamine in vitro. Finally, we were able to rescue dopaminergic neurons from dopamine toxicity by specifically inhibiting its interaction with α-synuclein in C. elegans. Dopamine-modified α-synuclein species may mediate neurodegeneration by disrupting cellular membranes, as previously proposed for α-synuclein oligomers 49 . Moreover, damage to synaptic vesicle membranes could lead to dopamine leakage and further induction of pathogenic α-synuclein species.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Animals. The mice (Mus musculus) used in this study were homozygous for expression of human A53T α-synuclein under the mouse PrP promoter (line M83). These mice undergo spinal cord degeneration at approximately 18 months of age in our colony, and the phenotype has been described previously 32 . Any animals showing symptoms of spinal cord degeneration, that is, hunched back, altered gait, or hindlimb paralysis, were excluded from the study. NonTg littermates were also used for experiments. No care was taken as to the sex of the animals. Mice were randomly assigned to the lentiviral vector injection groups and subsequent analyses, and the organization of experimental conditions was also random. Data collection and analyses were not performed blind to the conditions of the experiments except where otherwise indicated. All animal work was conducted according to National Institute of Health guide for the care and use of laboratory animals and in compliance with procedures approved by the Children's Hospital of Philadelphia Institutional Animal Care and Use Committee.
Production of lentiviral vectors and determination of titer.
Generation of human tyrosine hydroxylase-1 with mutation of R 37 R 38 to E 37 E 38 (TH-RREE) has been previously described 26 . The coding sequence was removed from the pcDNA3.1 vector and was subcloned into the self-inactivating pTY-linker lentiviral expression vector at the Pme1 site downstream of the CMV promoter. Generation of replication-deficient pseudotyped HIV-derived lentiviral vectors was achieved by transient co-transfection of HEK293T cells with the expression vector along with the vectors carrying the additional transcripts required for encapsulation, packaging and envelope proteins. 24 h after the cells were seeded into 150-mm dishes coated with poly-D-lysine they were transiently transfected with a mixture containing 550 µg of the pTY-TH-RREE expression vector, 357.5 µg of CMVD82 packaging vector, and 192.5 µg of pVSV-G envelope vectors using the calcium phosphate transfection protocol. The culture medium was changed every day and the media containing the virus was collected 72 h post-transfection, filtered through 0.45 µm membranes, and concentrated by ultracentrifugation at 50,000 g for 2 h at 4 °C. The viral pellet was subsequently re-suspended in 800 µl of DMEM medium to make a concentrated viral stock. An empty vector control virus containing all elements except for the gene encoding TH-RREE (CtrlVect) was generated in parallel and both viruses were obtained from the University of Pennsylvania Vector Core.
To determine vector functionality and viral titer, SH-SY5Y human neuroblastoma cells (American Type Culture Collection) were plated in 24-well plates at 5 × 10 4 cells/well in DMEM/F12 medium containing 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were allowed to recover for 2 d and were then differentiated for 5 d with 20 µM retinoic acid. The cells were infected with different dilutions of CtrlVect or TH-RREE lentivirus and viral titers were calculated by TH immunocytochemistry as described previously 26 for three independent cell plating/infection experiments.
Stereotaxic injection of lentiviral vector into the Sn.
A53T α-synuclein transgenic mice or non-transgenic littermates received bilateral lentiviral vector injections at 10 months of age. The mice were placed into an anesthesia chamber connected to an isofluorane delivery system to induce anesthesia. The mice were then placed into a stereotaxic head holder, an anesthesia mask was fitted, and an incision was made in the skin. Small bilateral holes were drilled into the skull according to the coordinates for the SN in the mouse brain (anterior-posterior −3.3 mm from bregma, mediolateral 1 mm) and a 30g Hamilton syringe was inserted slowly to 4 mm dorsoventral depth. 2 µl of the viral concentrate (5 × 10 7 IU/ml) was injected into the SN at a rate of 0.25 µl/min, and the needle was left in place for an additional 5 min before being slowly withdrawn, in order to minimize leakage of the injected fluid. The skin was sutured sterilely and the animals were monitored until they recovered from anesthesia. motor function testing. All behavioral tests were conducted 1 week before sacrifice. Mice were habituated to the testing room for 2 h before testing. To measure open field activity, the mice were singly housed and the cage was placed inside a laser monitoring device consisting of an open, rectangular frame containing sensors (Opto-M3 activity meter, Columbus Instruments). The number of infrared beam breaks was quantified over a 12-h period during the dark cycle from 6 p.m. to 6 a.m. using Multi Device Interface software version 1.3 (Columbus Instruments). For each animal, data was collected for up to 3 consecutive days and averaged. Food and water were available ad libitum.
To assess motor coordination and balance, mice were tested on the Rotarod (Ugo Basile, model 7650). The mice were acclimated to the apparatus with four training sessions of 5 min each at 4 rpm, followed by 5 min of rest in the home cage. Testing was performed 1 h later with two trials in which speed was accelerated from 4 to 40 rpm in 300 s. For each mouse, the latency to fall off the rotarod within this time period was recorded for the two trials and averaged.
Immunohistochemistry and stereological cell counts. For histological analysis, the mice were deeply anesthetized and perfused transcardially with saline followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). The brains were post-fixed overnight at 4 °C in 4% PFA and then cryoprotected in 30% sucrose solution for 2 d at 4 °C. The brains were submerged in dry icechilled isopentane for 30 s and then stored at −80 °C until sectioning. On the day of sectioning, brains were mounted on chucks with OCT (Tissue-Tek) and the brainstem, SN and striatum were each sectioned using a cryostat (Leica, Jung Frigocut 2800N). Free-floating coronal sections of alternating 10-and 30-µm thickness were collected from each region and stored at 4 °C in 0.1 M phosphate buffer containing 0.01% sodium azide.
The sections were quenched in 5% H 2 O 2 in methanol for 30 min, followed by antigen retrieval by boiling in citrate solution pH 6 for 10 min. The tissue was blocked for 1 h at 20−25 °C with 5% NGS, 3% BSA in PBS containing 0.1% Triton X-100, and then incubated overnight at 4 °C with primary antibody diluted in blocking buffer. Antibodies were used against VMAT2 (rabbit, 1:20,000, Covance Custom Immunology Services; courtesy of G. Miller, Emory University) 43 , TH (rabbit, 1:2,000, Calbiochem 657012) 51 , and Syn505 (mouse, 1:5,000, courtesy of V.M. Lee, University of Pennsylvania) 32 . Incubation with biotin-conjugated secondary antibodies was followed by avidin-biotin-peroxidase complex, each for 1 h at 20−25 °C (Vector Laboratories PK-6101, PK-6102) 34 , and visualization by 3,3-diaminobenzidine (DAB) for 1 min (Vector Laboratories). In some cases, sections were counterstained with Cresyl Violet. The tissue was then mounted, dehydrated in an increasing alcohol series and cleared in xylenes, and coverslipped with Permount mounting medium. Slides were scanned by the Children's Hospital of Philadelphia Pathology Core facility and images were accessed using Aperio Imagescope software version 11.2 (Leica Biosystems). Quantification of VMAT2 staining intensity in the striatum was performed using Image J software version 1.48 (National Institutes of Health).
Unbiased stereological quantification of neurons in the SN was performed as described previously 33 . Briefly, 30-µm sections spaced 90 µm apart were selected in order to represent the full rostro-caudal axis of the SN. The sections were stained with Cresyl Violet and the Nissl-positive neurons were blindly counted using the optical fractionator method (StereoInvestigator version 11.02.1, MBF Bioscience). catechol quantification by HPlc with electrochemical detection. Striatal tissues were homogenized by sonication in ten volumes of 0.1 M perchloric acid containing 1 µM 3,4 dihydroxybenzylamine as an internal standard. The samples were centrifuged at 16,000 g for 10 min at 4 °C and the supernatants were filtered through 0.22-µm filters. 50 µl of each sample was injected onto an Agilent 1100 series HPLC controlled by ChemStation software version 1.04 (Agilent). Catechols were resolved on a reverse-phase C18 Luna column (150 × 4.6 mm, 5 µm; Phenomenex) and detected using a Coularray detector (ESA Biosciences) as previously described 26 . Protein pellets were solubilized in 50 mM Tris pH 7.4 containing 2% SDS and protein concentration was determined using the BCA microassay kit (Pierce). Monoamine levels were normalized to protein concentration and expressed as femtomoles analyte per µg of protein.
Sequential extraction and native Sec. Striatal or SN tissue from individual mice was homogenized in ten volumes of lysis buffer: 1% Triton X-100 in 20 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EGTA, and protease inhibitor cocktail (P2714, Sigma). The tissue was grinded with a mechanical homogenizer and centrifuged at 16,000 g for 10 min at 4 °C. The pellet was further extracted by sonication in 2% SDS, 50 mM Tris pH 7.4 with protease inhibitor cocktail, boiling at 95 °C for 10 min, and centrifugation at 16,000 g for 10 min. The resulting supernatant was designated the Triton-insoluble fraction. Protein concentration was determined using the BCA assay (Pierce).
For SEC, 500 µg of Triton-soluble SN tissue in a total volume of 270 µl was loaded onto a Superdex 200 HR10/30 column (GE Healthcare) connected to an Following 1 week in culture, neurons were treated with dopamine-incubated α-synuclein (from day 4-6 of in vitro aggregation) at a final concentration of 1 µM. Control conditions were equivalent doses of PBS, monomeric αsynuclein, or dopamine that had been incubated in parallel under aggregation conditions but without α-synuclein. 2 weeks post-treatment, cell viability was assayed using calcein AM (Sigma) and propidium iodide (PI) (Sigma) incubated for 20 min at 20−25 °C at final concentrations of 3 µM in PBS. Fluorescence images were obtained using MetaMorph software version 7.7 (Molecular Devices) and an inverted Olympus IX70 microscope equipped with an IX-FLA fluorescence observation attachment (Olympus Optical). For quantification of viable cells (calcein positive and PI negative), at least ten random fields of view were blindly counted per treatment condition and averaged to obtain one replicate value. Independent culture experiments performed with separate plating/treatments were considered independent replicates and were reported as the n value.
To image human α-synuclein in treated neurons, cells were labeled in a twostage protocol as previously described 63 . 2 weeks following treatment, cells were live-incubated in media containing Syn204 antibody (mouse IgG2a, 1:500) for 1 h at 4 °C to label extracellular α-synuclein. The cells were then fixed with 4% PFA for 20 min at 20−25 °C, and permeabilized with 0.1% Triton X-100 in 5% NGS, 3% BSA in PBS for 1 h at 20−25 °C. Cells were incubated with LB509 (mouse IgG1, 1:500) overnight at 4 °C to label both extracellular and intracellular α-synuclein. Secondary antibodies conjugated to Alexa Fluor (anti-mouse IgG1 488, 1:500, Thermo Fisher A21121; anti-mouse IgG2a 594, 1:500, Thermo Fisher A-21135) were incubated for 1 h at 20−25 °C. The staining was imaged by laser-scanning confocal microscopy (Olympus Fluoview) and the n value equals the number of independent culture experiments.
Statistics. All statistical analysis was done using Prism 6 software (GraphPad). Two-tailed unpaired Student's t test was used for all comparisons between two groups. For comparisons with multiple groups, one-way ANOVA using Tukey's post hoc correction for multiple comparisons. Specifically for Thioflavin T assays with multiple groups measured over time, repeated-measures two-way ANOVA with Tukey's or Bonferroni's correction for multiple comparisons was used. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported previously 34, 36 . All experiments were performed at least twice, with measurements from the same samples treated as technical replicates. In the case of representative images, several images per sample were obtained. Readers are referred to the life Sciences Reporting Summary available online for additional information.
data Availability Statement. The data that support the findings of this study are available from the corresponding author upon reasonable request. 
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were randomly assigned to the lentiviral vector injection groups and subsequent analyses. Transgenic worms were randomly chosen for analysis.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Data collection and analyses were not performed blind to the conditions of the experiments except for stereological quantification of neurons, and counting of cells in culture.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
All statistical analysis was done using Prism 6 (GraphPad). Open field testing used Multi Device Interface version 1.3 (Columbus Instruments). Images of tissue staining were accessed using Aperio Imagescope version 11.2 (Leica Biosystems) and quantification of staining was performed using Image J version 1.48 (National Institutes of Health). Stereological cell counts were done using StereoInvestigator version 11.02.1 (MBF Bioscience). HPLC analyses were done using ChemStation version 1.04 (Agilent), and catechol quantification additionally used ESA CoulArray version 3.10. Fluorescence images were obtained using MetaMorph version 7.7 (Molecular Devices). Western blot band intensities were quantified using ImageStudio software version 4.0.21 (Li-Cor).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no restrictions on availability of unique materials, such as TH-RREE and CtrlVect plasmids.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The following antibodies were used: VMAT2 (Covance Custom Immunology Services, ref. 43 c. Report whether the cell lines were tested for mycoplasma contamination.
No test for mycoplasma contamination was performed.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
The mice (Mus musculus) used in this study were homozygous for expression of human A53T α-synuclein under the mouse PrP promoter (line M83) (ref. 32) , and non-transgenic littermates. No care was taken as to the sex of the animals. Mice were 10 months old at viral injection and either 12.5 or 15 months old at analysis. Four transgenic C. elegans strains were generated and hermaphrodites were analyzed at 3, 5, and 6 days post-hatching. Primary neuronal cultures were derived from C57BL/6 mouse embryos at day [18] [19] .
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
